论文部分内容阅读
心律平(Propafenone;Rytmonrm)是继乙胺碘呋酮之后又一高效、新型、广谱抗心律失常药物。该药1975年首先在西德应用,国内1982年正式应用于临床,经临床初步使用证明:心律平可治疗早搏,阵发性室上性心功过速或室性心动过速,房颤房扑及预激综合症等异位心律失常。其疗效确切,起效迅速,作用时间持久,是一种优良的高效抗心律失常药物。一、药理作用: 经动物实验和临床资料表明:心律平的抗心律失常机理为直接作用于心肌细胞膜,
Propafenone (Rytmonrm) is another highly effective, new, broad-spectrum antiarrhythmic drug following amiodarone. The drug first applied in West Germany in 1975, the domestic formally applied in clinical in 1982, the initial clinical use of Prove: Cardiac therapy can treat premature beats, paroxysmal supraventricular tachycardia or ventricular tachycardia, atrial fibrillation Flutter and pre-excitation syndrome and other ectopic arrhythmias. The exact effect, rapid onset, long duration of action, is an excellent and effective anti-arrhythmic drugs. First, the pharmacological effects: animal experiments and clinical data show that: the anti-arrhythmic mechanism of heart rhythm is a direct effect on the myocardial cell membrane,